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Abstract
Tuberculosis (TB) granulomas are organized collections of immune cells comprised of macrophages, lymphocytes and other
cells that form in the lung as a result of immune response to Mycobacterium tuberculosis (Mtb) infection. Formation and
maintenance of granulomas are essential for control of Mtb infection and are regulated in part by a pro-inflammatory
cytokine, tumor necrosis factor-a (TNF). To characterize mechanisms that control TNF availability within a TB granuloma, we
developed a multi-scale two compartment partial differential equation model that describes a granuloma as a collection of
immune cells forming concentric layers and includes TNF/TNF receptor binding and trafficking processes. We used the
results of sensitivity analysis as a tool to identify experiments to measure critical model parameters in an artificial
experimental model of a TB granuloma induced in the lungs of mice following injection of mycobacterial antigen-coated
beads. Using our model, we then demonstrated that the organization of immune cells within a TB granuloma as well as
TNF/TNF receptor binding and intracellular trafficking are two important factors that control TNF availability and may
spatially coordinate TNF-induced immunological functions within a granuloma. Further, we showed that the neutralization
power of TNF-neutralizing drugs depends on their TNF binding characteristics, including TNF binding kinetics, ability to bind
to membrane-bound TNF and TNF binding stoichiometry. To further elucidate the role of TNF in the process of granuloma
development, our modeling and experimental findings on TNF-associated molecular scale aspects of the granuloma can be
incorporated into larger scale models describing the immune response to TB infection. Ultimately, these modeling and
experimental results can help identify new strategies for TB disease control/therapy.
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Introduction
Tuberculosis (TB) is caused by a highly successful bacterium,
Mycobacterium tuberculosis (Mtb), and is responsible for three million
deaths per year [1]. 5–10% of infected people fail to control the
infection and progress to primary TB disease [2]. A state of latent
infection with no clinical symptoms is achieved in most people and
may be maintained for the lifetime of the host. However, latent
infection can be reactivated years later leading to active
tuberculosis. The risk of reactivation is increased in latently
infected persons who are elderly, immunocompromised (e.g. due
to HIV co-infection), malnourished or taking specific drugs [3,4].
A key outcome of Mtb infection that arises as a result of the
immune response within the host is the formation of aggregates of
immune cells and bacteria called granulomas in the lungs. TB
granulomas, especially in humans as well as guinea pig and non-
human primate models, form as organized spherical structures
composed of a core of bacteria, macrophages and dendritic cells
(DCs) surrounded by a ring of lymphocytes, including T cells and
B cells [2,5–10]. In an infected host with latent infection, the
micro-environment created within a granuloma provides appro-
priate conditions for containment of bacteria [11,12].
Tumor necrosis factor-a (TNF) is a well-studied inflammatory
cytokine that is produced by immune cells, especially activated
macrophages and monocytes. TNF is expressed as a 26 kDa
membrane-bound precursor protein (membrane-bound TNF;
mTNF) that can be cleaved by proteolytic activity of a
metalloproteinase TNF-a converting enzyme (TACE) and re-
leased as a 17 kDa subunit (soluble TNF; sTNF) into extracellular
spaces [13,14]. Both sTNF and mTNF are trimeric in their mature
bioactive form [15] and function by binding to one of the two
types of TNF receptors on cells: TNF receptor type 1 (TNFR1;
also referred to as p55 or CD120a) and TNF receptor type 2
(TNFR2; also called p75 or CD120b) [16]. Although the two
receptors are co-expressed on the surface of most cell types,
TNFR1 has been identified as the primary signaling receptor
through which most of the inflammatory responses attributed to
TNF occur [17]. TNF affects the immune response to Mtb
through several mechanisms, including induction of macrophage
activation [18], apoptosis [19,20], and chemokine expression [21].
Further, numerous reports have begun to reveal the role of TNF in
granuloma formation as well as in maintenance of granulomas in
latent TB [11,18,22–24]. There are conflicting data, however,
regarding the role of TNF in granulomas and Mtb infection and
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anti-inflammatory TNF-neutralizing drugs such as infliximab and
etanercept are associated with an increased risk of latent TB
reactivation, although the level of susceptibility depends on the
drug [25,26]. Granuloma formation in mice that lack TNF or
TNFR1 has been reported to be aberrant or delayed [18].
Neutralization of TNF in mice with chronic infection leads to
disorganization of granulomas, increase in bacterial load and
subsequent death [23]. However, TNF neutralization in monkeys
results in both exacerbation of primary disease and reactivation of
latent infection without affecting the granuloma architecture seen
in primary and latent TB [27]. Overall, it is clear that TNF plays
an important role in TB infection dynamics. Further, TNF
availability, i.e. the amount of TNF available to cells in the
granuloma, has been reported to be crucial in control of TB
infection [28,29], but there are still open questions regarding the
mechanisms controlling TNF availability and the influence of
TNF availability on granuloma function.
To elucidate the mechanisms by which availability of TNF in a
granuloma is controlled, we focus on TNF interactions with
immune cells that comprise a granuloma. We are interested
particularly in TNF receptor dynamics. Receptor/ligand interac-
tions at the cell membrane are responsible for initiating
intracellular signaling pathways and ultimately the cell response
to the external stimulus. However, trafficking events (defined here
to include synthesis, internalization, recycling and degradation of
ligands and receptors) have been demonstrated to take place under
normal physiological conditions and can influence the availability
of ligand, the number of ligand-bound receptors and thus
receptor-mediated cell responses [30,31]. TNF/TNFR trafficking
processes have been studied in a variety of human and mouse cell
lines [32–36]. For example, a whole-cell kinetic analysis of TNF/
TNFR system with fitting to experimental data on human lung
adenocarcinoma A549 cells has shown that the simplest model
that reasonably explains the behavior of this system includes
receptor synthesis and turn-over, TNF/TNFR association and
dissociation as well as TNF/TNFR complex internalization,
degradation and recycling of free receptors to the cell membrane
[36].
The influence of the dynamics of TNF/TNFR trafficking
processes on the availability of TNF in a TB granuloma has never
been studied. Thus, we develop a reaction/diffusion-based partial
differential equation (PDE) model that describes a TB granuloma as
a continuous collection of immune cells forming concentric layers
and includes TNF/TNFR binding and trafficking processes. Our
multi-scale model is focused on TNF/TNFR-level reactions and
interactions, while using a coarse-grain description of the cellular-
level details representing a snapshot in time of a granuloma
comprised of a static number of immune cells. To analyze the
model, we use estimations for TNF/TNFR-associated parameter
values from literature and then employ an artificial experimental
mouse model of TB granuloma (Figure 1) to quantitatively measure
critical model parameters identified by sensitivity analysis. The
artificialmodel of granulomaformationis induced inmicefollowing
Author Summary
Tuberculosis is a common and deadly infectious disease
caused by a highly successful bacterium, Mycobacterium
tuberculosis (Mtb). Multiple host immune factors control
the formation of a self-organizing aggregate of immune
cells termed a granuloma in the lungs after inhalation of
Mtb. One such factor, tumor necrosis factor-a (TNF), is a
protein that regulates inflammatory immune responses.
Availability of TNF within a TB granuloma has been
proposed to have a critical role in the protective immunity
against TB. However, direct measurement of the level of
TNF in a granuloma is not experimentally feasible.
Therefore, we develop a mathematical model based on
an experimental model of granuloma developed in mice to
predict TNF availability in a granuloma. We measure values
of critical model parameters and explore mechanisms that
influence TNF availability in the granuloma. We find that
cellular organization in a granuloma and intracellular
trafficking of TNF control TNF availability in a granuloma.
Further, our model analysis also highlights anti-TNF drug
properties that determine their TNF neutralization power.
Our findings complement and extend those of recent
studies on the role of TNF in the immune response against
TB.
Figure 1. PPD antigen-bead pulmonary granuloma model. (A) Schematic representation (rbead: radius of bead, rg: radius of granuloma) and (B)
histological appearance of an artificial pulmonary granuloma induced in mouse 4 days after injection of PPD-coated beads [37,38,41] (H&E staining;
magnification: 6800).
doi:10.1371/journal.pcbi.1000778.g001
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purified protein derivative (PPD) antigen. This model is an
appropriate choice for our study as it provides cytokine and cellular
patterns that closely match those in an active mycobacterial
infection [37–41]. Thus our mathematical model also accounts
for a bead at the center of the granuloma (Figure 1). We use our
model to answer the following questions: What are the most
important processes that control TNF availability in a granuloma?
Are there likely to be gradients of TNF within a TB granuloma?
How does the specific organization of immune cells in the
granuloma, i.e. a core of macrophages and DCs surrounded by a
mantle of lymphocytes, influence the fraction of TNF-bound
receptors and thus TNFsignalingforeachcelltype? And ultimately,
how might the neutralization power of TNF-neutralizing drugs in a
TB granuloma be affected by their TNF binding properties?
Methods
Ethics statement
Animal studies were conducted according to University of
Michigan Committee on Use and Care of Animal (UCUCA)-
approved protocol (No. 8307).
TNF/TNFR kinetics at the single-cell level
The binding interactions and reactions controlling TNF/TNFR
dynamics at the single-cell level regardless of the cell type are
illustrated in Figure 2A. TNF is first synthesized by TNF-producing
cells as a membrane-bound precursor form (mTNF) that can then
beprocessedandreleasedasasolubleform(sTNF)intoextracellular
spaces. This processing occurs via a cell-associated metalloprotei-
nase called TACE [13,14]. Two types of TNF receptors (TNFR1
and TNFR2) are synthesized and expressed on the cell surface as
free receptors. Soluble TNF (sTNF) reversibly binds to TNFRs on
the cell membrane or degrades [16,42,43]. sTNF-bound cell surface
TNFR1 internalizes and sTNF-bound cell surface TNFR2 may
undergo internalization or shedding into extracellular spaces [44].
Internalized receptors may degrade or recycle to the cell membrane
where they can re-bind to sTNF [36]. Ligand-free TNFRs also turn
over (internalize) [34,36]. Intact sTNF may dissociate from the shed
sTNF/TNFR2 complex in the extracellular space [45]. We
modeled these molecular processes based on mass action kinetics
as shown in Tables 1 and 2; definitions and values of the rate
constants are given in Table 3.
TNF neutralization kinetics
Several TNF-neutralizing drugs have been developed and they
work to interfere with TNF activity and thus are used to control
inflammation in human diseases such as rheumatoid arthritis and
Crohn’s disease. These drugs are composed of either monoclonal
antibodies (e.g. infliximab) or receptor fusion molecules (e.g.
etanercept) that specifically bind TNF, acting as a competitive
inhibitor for TNF binding to cell surface TNFRs and eventually
neutralizing its functions [46,47].
To study the effect of TNF-neutralizing drugs of various
properties on TNF/TNFR dynamics, we modeled a hypothetical
drug as an agent that binds to sTNF or both sTNF and mTNF
molecules and also inhibits sTNF binding to both TNFRs. We
captured TNF neutralization-associated reactions (schematically
shown in Figure 2B) in our model, including reversible binding of
drug to mTNF and sTNF [47,48], release of drug-bound mTNF
into extracellular spaces due to TACE activity, and drug or TNF/
drug complex degradation [49] based on mass action kinetics as
shown in Table 2. Definitions and values of drug-specific
parameters are given in Table 4.
Two-compartment model of granuloma
To study the influence of TNF/TNFR dynamics on the availability
of TNF within the multi-cellular structure of the granuloma, TNF/
TNFR-associated molecular processes described at the single-cell level
were incorporated into a coarse-grain multi-cellular model of a TB
granuloma. The model represents a snapshot in time of a granuloma
and is composed of an organized collection of a static number of
immune cells surrounding a PPD-coated bead. Within this collection,
TNF is produced by TNF-producing immune cells, diffuses in
extracellular spaces and interacts with TNFR-expressing cells. We
modeled the granuloma as a spherical continuum consisting of two
cellular compartments. The inner compartment includes evenly
distributedmacrophagesand DCsthat formthe core ofthe granuloma,
and the outer compartment or mantle is comprised of evenly
distributed T cells and B cells (Figure 2C). This is consistent with the
structure observed for classical TB granulomas that are comprised of
aggregates of macrophages and DCs with a characteristic cuff of
lymphocytes, including T cells and B cells on the periphery [2,6].
Discrete cells are not explicitly considered in this model; each cell-
associated species (e.g. cell surface TNF receptor, internalized TNF-
bound receptor, etc) is treated as a spatially immobile agent whose
concentration in space is expressed by a continuous variable, whereas
unbound extracellular sTNF and shed receptors are free to diffuse.
Thus, the model includes reaction-diffusion equations for extracellular
sTNF and shed receptor concentrations, and basic reaction equations
for other species as listed in Table 5. Definitions and values of model
parameters are given in Table 3.
To maintain the consistency of the mathematical model with the
experimental mouse bead model of granuloma that we study, the
granuloma is comprised of a bead of radius rbead surrounded by
cellular layers of the inner and outer compartments with radii of rcore
and rg, respectively (Figure 2C). We assumed no flux of sTNF at
r=rbead and at r=rm, a distance equal to half the mean distance
between granulomas, due to symmetry with tissue surrounding
adjacent granulomas. Initial conditions for TNFRs are specified as:
½TNFR1 (r,0 ) ~
R1 in : rbeadvrƒrcore
R1 out : rcorevrƒrg
ð1Þ
½TNFR2 (r,0 ) ~
R2 in : rbeadvrƒrcore
R2 out : rcorevrƒrg
ð2Þ
where R1_in, R1_out, R2_in and R2_out are the average TNFR1 and
TNFR2 densities on the membrane of cells in the inner and outer
compartments. These parameters were set equal to the steady state
concentrations of cell surface TNFRs in each compartment in the
absence of TNF and are controlled by the rates of receptor synthesis
and turnover of free receptors as indicated in Table 3. Similarly, we
assumed the steady state concentration of mTNF (found from
Equation 3) in each compartment as the initial value of mTNF for
that compartment (Equation 4).
d½mTNF 
dt
Dsready-state ~ksynth{kTACE½mTNF steady{state~0 ð3Þ
½mTNF (r,0 ) ~½mTNF steady{state
~
ksynth in
 
kTACE : rbeadvrƒrcore
ksynth out
 
kTACE : rcorevrƒrg
ð4Þ
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associated mTNF is the initial source of the whole TNF in the
granuloma.
The PDE model was solved numerically using COMSOL
Multiphysics 3.4 (COMSOL AB, Stockholm, Sweden) with
MATLAB 7.5 (The MathWorks, Natick, MA). Simulations were
run until a steady state was reached (approximately 12 hours of
real time). Because TNF-associated molecular level processes
studied here occur significantly faster than cellular level events that
may change the structure of a granuloma (e.g. cell recruitment,
migration and death), we assumed that the structure of granuloma
is not changed during the 12-hour time course of simulations.
Distinct cell types and cellular organization in the
granuloma model
To study the influence that specific cellular organizations may
have on the availability of TNF within a TB granuloma, we
explicitly incorporated major granuloma-comprising cell types
(determined from experiments performed herein), including
macrophages, DCs, T cells and B cells into our mathematical
Figure 2. Schematic representation of the multi-scale two-compartment model of PPD bead granuloma and TNF-associated
reactions. (A) Binding interactions and reactions controlling TNF/TNFR dynamics at the single-cell level, including synthesis of TNFR1, TNFR2 and
mTNF, sTNF release to the extracellular space under the effect of TACE activity, reversible binding of sTNF to TNFR1 and TNFR2, sTNF degradation,
internalization of free and sTNF-bound TNFR1 and TNFR2, degradation of internalized TNFR1 and TNFR2, recycling of internalized TNFR1 and TNFR2,
shedding of sTNF-bound TNFR2 and release of sTNF from the shed sTNF/TNFR2 complex. (B) TNF neutralization-associated reactions, including
reversible binding of drug to mTNF and sTNF, release of drug-bound TNF from the membrane to the extracellular space and drug degradation. (C)
Two-compartment model of granuloma that includes a bead of radius rbead surrounded by the inner compartment populated by macrophages and
DCs and the outer compartment composed of lymphocytes. Numbers in (A) and (B) represent model reactions as listed in Table 2.
doi:10.1371/journal.pcbi.1000778.g002
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present the level of separation between different cell types in a
granuloma, defined as:
s~
lo{lg
1{lg
ð5Þ
where lo, lg are the lymphocyte (T cells and B cells) fractions in the
outer compartment and in the whole granuloma, respectively.
Thus a separation index of 0 is equivalent to a totally mixed
cellular organization, whereas a separation index of 1 represents a
separate cellular organization approximately as observed in
human and non-human primate models of TB in which DCs
and macrophages reside in the inner compartment (core) and
lymphocytes compose the outer compartment (mantle). A
schematic representation of the effect of changing s on cellular
organization of the bead granuloma is shown in Supplementary
Figure S1(A). Some model parameters were also defined or
modified based on consideration of the cellular organization in the
model as shown in Supplementary Table S1. For example, using
the mean cell volume in each compartment, cell number densities
in the inner and outer compartments (rin and rout) are computed
and replace general cell density r in diffusion equations of Table 5.
We assumed that some TNF/TNFR kinetic parameters,
including the rate constants for TNF release by TACE activity,
TNF/TNFR association and dissociation as well as TNFR
Table 1. Definition of reaction species.
Reaction species
mTNF Membrane-bound TNF sTNF/TNFR1i Internalized sTNF/TNFR1 complex
sTNF Extracellular soluble TNF sTNF/TNFR2i Internalized sTNF/TNFR2 complex
TNFR1 Cell surface TNF receptor 1 sTNF/TNFR2shed Shed sTNF/TNFR2 complex
TNFR2 Cell surface TNF receptor 2 Drug TNF-neutralizing drug
sTNF/TNFR1 sTNF/TNFR1 complex on the membrane mTNF/Drug mTNF/Drug complex on the membrane
sTNF/TNFR2 sTNF/TNFR2 complex on the membrane sTNF/Drug Extracellular sTNF/Drug complex
doi:10.1371/journal.pcbi.1000778.t001
Table 2. Model reaction and their rates (vi).
Base model reactions
1 mTNF synthesis v1~ksynth
2 mTNFRsTNF v2~kTACE½mTNF 
3 sTNF+TNFR1«sTNF/TNFR1 v3~kon1½sTNF ½TNFR1 {koff1½sTNF=TNFR1 
4 sTNF+TNFR2«sTNF/TNFR2 v4~kon2½sTNF ½TNFR2 {koff2½sTNF=TNFR2 
5 sTNFRdegradation v5~kdeg½sTNF 
6 sTNF/TNFR1RsTNF/TNFR1i v6~kint1½sTNF=TNFR1 
7 sTNF/TNFR2RsTNF/TNFR2i v7~kint2½sTNF=TNFR2 
8 sTNF/TNFR2RsTNF/TNFR2shed v8~kshed½sTNF=TNFR2 
9 TNFR1 synthesis v9~Vr1
10 TNFR2 synthesis v10~Vr2
11 TNFR1RTNFR1i v11~kt1½TNFR1 
12 TNFR2RTNFR2i v12~kt2½TNFR2 
13 sTNF/TNFR1iRdegradation v13~kdeg1½sTNF=TNFR1i 
14 sTNF/TNFR2iRdegradation v14~kdeg2½sTNF=TNFR2i 
15 sTNF/TNFR1iRTNFR1 v15~krec1½sTNF=TNFR1i 
16 sTNF/TNFR2iRTNFR2 v16~krec2½sTNF=TNFR2i 
17 sTNF/TNFR2shedRsTNF+TNFR2shed v17~koff2½sTNF=TNFR2shed 
TNF neutralization reactions
18
* mTNF+Drug«mTNF/Drug v18~kon TNF=Drug½mTNF ½Drug {koff TNF=Drug½mTNF=Drug 
19 mTNF/DrugRsTNF/Drug v19~kTACE½mTNF=Drug 
20
* sTNF+Drug«sTNF/Drug v20~kon TNF=Drug½sTNF ½Drug {koff TNF=Drug½sTNF=Drug 
21 DrugRdegradation v21~kdeg Drug½Drug 
22 sTNF/DrugRDrug (sTNF degradation) v22~kdeg½sTNF=Drug 
23 sTNF/DrugRdegradation v23~kdeg Drug½sTNF=Drug 
*Sequential binding of drug to sTNF and mTNF for drugs with TNF binding ratio of greater than 1:1 was modeled similarly.
doi:10.1371/journal.pcbi.1000778.t002
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values for different cell types. This assumption is based on
consistency of experimental data on measurement or estimation of
values ofthese parameters for a variety of celltypes including various
celllines expressing TNF and/or TNF receptors with one another as
well as other data on similar mammalian cell surface receptors
[14,30,32–34,36,42,44,50–53]. However, the rate of synthesis of
TNF and TNFRs depends on the cell type (see Results). Thus, when
different cell types are considered, average rates of mTNF synthesis
in granuloma compartments can be computed as follows:
ksynth in~(1{s)(fBkBzfCD4kCD4zfCD8kCD8)
z
½1{lg(1{s) (fMackMaczfmDCkmDCzfpDCkpDC)
1{lg
ð6Þ
Table 3. Model parameters, definitions and values estimated from literature.
Parameter Parameter description Value
* Reference
ksynth in (#/cell.s) Average rate of mTNF synthesis in the inner compartment 10
22–1 See text
ksynth out (#/cell.s) Average rate of mTNF synthesis in the outer compartment 0–10
21 See text
R1 out (#/cell) TNFR1 density in the outer compartment 500–5000 [33,60,61]
R1i n(#/cell) TNFR1 density in the inner compartment 500–5000 [33,60,61]
R2 out (#/cell) TNFR2 density in the outer compartment 500–5000 [33,60,61]
R2i n(#/cell) TNFR2 density in the inner compartment 500–5000 [33,60,61]
f Fraction of granuloma in the outer compartment 0.4–0.7 [7,41]
D1 (cm
2/s)
{ Diffusion coefficient of sTNF 10
28–10
27 (5.2610
28) [88,89]
D2 (cm
2/s)
{ Diffusion coefficient of shed TNF/TNFR2 complex 10
28–10
27 (3.2610
28) [88,89]
w
{ Volume fraction of the extracellular space per granuloma volume 0.2–0.3 (0.2) [90,91]
dG (#/mm
2) Density of granulomas in the lung tissue cross section 0.5–30 (1) [92,93]
r (cell/l) Mean cell number density in the tissue 6610
12 [41]
rg (mm) Granuloma radius 100 [41]
rm (mm)
1 Half mean distance between granulomas 10006(pdG)
20.5
rbead (mm) Bead radius 40
rcore (mm) Radius of the inner compartment [rg
32f(rg
32rbead
3)]
1/3
Nav (mol
21) Avogadro’s number 6.02610
23
kTACE (s
21) Rate constant for TNF release by TACE activity 10
24–10
23 (4.4610
24) [14,50,51]
kdeg (s
21) sTNF degradation rate constant 4.58610
24 [74]
Kd1 (M) Equilibrium dissociation constant of sTNF/TNFR1 10
212–10
210 (1.9610
211) [33,42]
Kd2 (M) Equilibrium dissociation constant of sTNF/TNFR2 10
210–10
29 (4.2610
210) [33,42,53]
kon1 (M
21s
21) sTNF/TNFR1 association rate constant 10
7210
8 (2.8610
7) [42]
kon2 (M
21s
21) sTNF/TNFR2 association rate constant 10
7210
8 (3.5610
7) [42]
koff1 (s
21) sTNF/TNFR1 dissociation rate constant kon16Kd1
koff2 (s
21) sTNF/TNFR2 dissociation rate constant kon26Kd2
kint1 (s
21) TNFR1 internalization rate constant 5610
24–1.5610
23 (7.7610
24) [42,44]
kint2 (s
21) TNFR2 internalization rate constant 3.9610
24–5610
24 (4.6610
24) [53]
kshed (s
21) TNFR2 shedding rate constant 3.9610
24–1.5610
23 (5610
24) [44,50]
krec1 (s
21) TNFR1 recycling rate constant 8.8610
25–5.5610
24 (1.8610
25) [34,36]
krec2 (s
21) TNFR2 recycling rate constant 8.8610
25–5.5610
24 (1.8610
25) [34,36]
kt1 (s
21) TNFR1 turn-over rate constant 3610
24–5610
24 (3.8610
24) [34,36]
kt2 (s
21) TNFR2 turn-over rate constant 3610
24–5610
24 (3.8610
24) [34,36]
kdeg1 (s
21) TNFR1 degradation rate constant 10
25–10
24 (5610
25) [32–34,36]
kdeg2 (s
21) TNFR2 degradation rate constant 10
25–10
24 (5610
25) [32–34,36]
Vr1 in (#/cell.s) Cell surface TNFR1 synthesis rate constant in the inner compartment kt16R1_in
Vr1 out (#/cell.s) Cell surface TNFR1 synthesis rate constant in the outer compartment kt16R1_out
Vr2 in (#/cell.s) Cell surface TNFR2 synthesis rate constant in the inner compartment kt26R2_in
Vr2 out (#/cell.s) Cell surface TNFR2 synthesis rate constant in the outer compartment kt26R2_out
*The 25 parameters used for sensitivity analysis are indicated by their ranges of values. Values in parentheses are used to generate other model results.
{Diffusion coefficients of the soluble species in granuloma were estimated in line with estimates for diffusible factors of similar molecular weight in tumors [88,89].
{Consistent with extracellular volume fraction estimated for multi –cellular tumor spheroids [90,91].
1Half mean distance between granulomas were calculated from the granuloma density assessed for 2D sections of the lung tissue [92,93] and assumed to be consistent
in 3D.
doi:10.1371/journal.pcbi.1000778.t003
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½lg(1{s)zs (fBkBzfCD4kCD4zfCD8kCD8)
lg
z(1{s)(fMackMaczfmDCkmDCzfpDCkpDC)
ð7Þ
where definitions of parameters are given in Supplementary Table
S1. Similarly, average values of TNFR1 and TNFR2 densities in
each compartment can be computed.
Model outputs
The protective role of TNF in immunity to Mtb infection has
been shown to depend primarily on the soluble form (sTNF) and
its interactions with TNFR1 [18,54], suggesting that the spatial
profile of sTNF concentration and the fraction of sTNF-bound cell
surface TNFR1 are model outputs of interest. Therefore, we
introduce four steady-state spatially averaged metrics to charac-
terize our simulation results for availability of TNF in a
granuloma. These metrics were used to perform sensitivity analysis
and include: sTNF-bound fraction of cell surface TNFR1 in the
whole granuloma (output 1), granuloma core (inner compartment;
output 2) and mantle (outer compartment; output 3) as well as free
sTNF concentration in the whole granuloma (output 4).
Sensitivity analysis
Toidentifyparametersthatsignificantly influence the outcomes of
the two-compartment model of a granuloma, we used Latin
hypercube sampling (LHS) [55–59] to sample values of 25
parameters from the ranges (with uniform distributions) listed in
Table 3. Ranges of TNF/TNFR affinity and kinetic parameter
values were obtained from a variety of literature data from different
cell lines. However, no experimental values are available for several
other parameters, including the rate of mTNF synthesis and TNFR
densities as well as cell fractions and densities in a granuloma. Thus,
relevant ranges of values of these parameters, though not derived
fromTBgranulomas,were usedfor sensitivityanalysis. For example,
reported rates of TNF synthesis by activated cultured immune cells
[28,38], receptor densities on human monocytes and lymphocytes
[33,60,61], and immune cell fractions in the lungs of Mtb infected or
mycobacterial antigen activated mice [7,41] were used.
To reduce the number of parameters in LHS simulations, we
replaced distinct cell type fractions with a general parameter f
defined as the fraction of granuloma in the outer compartment. The
parameter f directly determines the thickness of the inner and outer
compartments as indicated in Supplementary Figure S1(B). The rate
of mTNF synthesis and density of TNF receptors were sampled
independently as average values of these parameters in each
compartment (ksynth_in, ksynth_out, R1_in, R1_out, R2_in, R2_out). Thus, these
parameters together with f determine the overall rate of TNF and
TNFR expression in the granuloma. Note that the separation index
(s) defined above is not used in the absence of distinct cell types (i.e.
for the sensitivity analysis described here). Simulations sampled each
parameter 1000 times, producing 1000 solutions to the model
equations. To determine the correlation between parameter values
and each of the model outputs, partial rank correlation coefficient
(PRCC) values were calculated [55,56,62]. PRCC values vary
between 21 (perfect negative correlation) and 1 (perfect positive
correlation)and can be differentiated based on p-values derived from
Student’s t test. The choice of number of simulations (N)i s
determined by the desired significance level for the PRCC [55,63]
and here N=1000 implies that PRCC values above +0.09 or below
20.09 are significantly different from zero (p,0.001). Model
parameters then were categorized for their significance in affecting
the model outputs based on their PRCC values.
Table 4. TNF neutralization-associated parameters, definitions, and values.
Parameter Parameter description Value Reference
Ddrug (cm
2/s)
* Diffusion coefficient of drug 2.3610
28 [88,89]
kc (cm/s)
{ Drug permeability in granuloma 9610
27 [94]
C0 (M)
{ Average drug concentration in the lung tissue 1610
27 [64,95]
kon TNF/Drug (M
21s
21) TNF/drug association rate constant 10
4–10
6 [48,83,84]
koff TNF/Drug (s
21) TNF/drug dissociation rate constant 10
25–10
23 [48,83,84]
kdeg Drug (s
21) Drug degradation rate constant 1610
26 [47]
*Diffusion coefficient of the drug in granuloma was estimated in line with estimates for diffusible factors of similar molecular weight in tumors [88,89].
{Drug permeability in granuloma was estimated based on permeability of bifunctional antibodies in tumors [94].
{Drug concentration in the lung was estimated based on approximate blood concentration of TNF-neutralizing drugs. For most antibodies, tissue/blood concentration
ratios are in the range of 0.1–0.5 [95].
doi:10.1371/journal.pcbi.1000778.t004
Table 5. Model equations.
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TNF neutralization reactions are distinguished from other reactions by bold font.
doi:10.1371/journal.pcbi.1000778.t005
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To study the effect of TNF-neutralizing drugs of various properties
on TNF availability in a granuloma, the model was run in the
absence of drug until a steady state was reached and then the drug
was added. We modeled the drug source as a concentration C0 in the
surrounding tissue with a flux into a granuloma that is dependent on
drug permeability kc and the drug gradient at granuloma radius r=rg:
Ddrug
L½Drug 
Lr Dr~rg~kc(C0{½Drug r~rg) ð8Þ
C0 was considered constant within the time course of simulation that
is significantly shorter than the decay time reported for TNF-
neutralizing drugs [47,64]. Equations describing drug/TNF interac-
tions and reactions are listed in Table 5. Drug-associated model
parameters are listed in Table 4. To compare the influence of drugs
with different properties (parameters) on availability of TNF in a
granuloma, TNF neutralization efficiency, E,w a sd e f i n e da sa
function of the ratio of the spatially averaged steady-state
concentration of sTNF before drug addition to the spatially averaged
concentration of sTNF when drug exerts its steady state maximum
effect, i.e. approximately 6 hours after drug addition.
E~1{
Ð rg
rbead ½sTNF Dt~6 hours(4pr2)dr
Ð rg
rbead ½sTNF Dt~0(4pr2)dr
ð9Þ
where t=0 stands for the steady state condition at which drug was
added.
Mouse model of TB granuloma
We use an artificial mouse model of TB granuloma that has been
demonstrated to provide a well-circumscribed lung granuloma
typified by a type 1 cytokine phenotype characterized in TB [38].
Briefly, granulomas were induced in pre-sensitized CBA/J mice lungs
following i.v. injection of 6000 Sepharose 4B beads (in 0.5 mlof PBS)
covalently coupled to Mycobacterium purified protein derivative (PPD)
as previously described [38,40,41,65]. After 2 days, PPD-coated
beads are surrounded by immune cells including macrophages, DCs,
T cells and B cells. PPD-bead granulomas achieve their maximal size
on day 4 and gradually diminish thereafter [38]. To measure
parameters of interest in PPD bead granulomas, groups of mice were
sacrificedat2and4daysafterbeadinjection.Intactgranulomaswere
isolated following homogenization of lungs in cold RPMI-1640
medium (BioWhittaker) in a Waring blender with a narrow-bottom
stainless steel cup. Granuloma cells were obtained following a 30-
minute treatment of isolated granulomas in a solution of RPMI
supplemented with 10% fetal calf serum (FCS), 1 mg/ml collagenase
A( R o c h e )a n d3 0mg/ml bovine pancreatic DNase I (Sigma) at 37uC
and used for further experiments.
Cellular composition of PPD bead granulomas
To identify the cellular composition of PPD bead granulomas, we
used multi-color flow cytometry with fluorescing antibodies specific
for immune cell markers, including macrophages, DCs, T cells and
B cells. Other immune cells such as neutrophils and eosinophils
were not quantified as they have been shown to constitute only a
tiny fraction of PPD bead granulomas [41]. The following
antibodies/conjugates were used for staining of the cells: anti-
CD11b-APC (BD Pharmingen), anti-CD11c-FITC (BD Pharmin-
gen), anti-F4/80-APC-Cy7 (eBioscience), anti-B220-PerCP-Cy5.5
(BioLegend), anti-CD4-PE-Cy7 (BD Pharmingen) and anti-CD8a-
Biotin (BD Pharmingen)/Streptavidin-Pacific Orange (Invitrogen).
Dead cells were identified and excluded from analysis by staining
withthe Live/Dead Fixable Violet DeadCell Stain Kit (Invitrogen).
2610
5 events were counted using a BD-LSRII system flow
cytometer (BD Biosciences). F4/80
+ CD11b
+ macrophage, B220
+
CD11c
+ lymphoid dendritic cell (pDC), CD11b
+ CD11c
+ myeloid
dendritic cell (mDC), B220
+ B cell, CD4
+ T cell and CD8
+ T cell
populations were gated following compensation for fluorochrome
spectral overlaps. Cell fractions in granulomas were identified
following analysis by FlowJo software (Treestar, Ashland, OR).
TNF receptor quantification
To quantify the number of TNFR1 and TNFR2 molecules on the
membraneofeachcelltype,weusedquantitativeflowcytometrywith
Phycoerythrin (PE)-conjugated anti-TNFR1 or -TNFR2 antibodies
(BioLegend), together with staining of cell-specific markers as
described above. Thus, cell suspensions at a concentration of
1610
6 cells per volume of 200 ml were stained with saturating
concentrations of antibodies that were identified to be 2 mg/l for
anti-TNFR1and1 mg/lfor anti-TNFR2 antibodies. We generated a
calibration plot from the fluorescence intensity measurements on
Quanti-BRITE PE-conjugated standard micro-beads (BD Bioscienc-
es). This plot was used (after compensation for fluorochrome spectral
overlaps) to quantify TNFR1 and TNFR2 densities on the
membrane of granuloma macrophages, mDCs, pDCs, B cells,
CD4 and CD8 T cells based on the PE mean fluorescence intensities.
Quantification of the rate of TNF synthesis
Because TNF is initially synthesized as a membrane-bound
molecule (mTNF), we can also use quantitative flow cytometry to
quantify the rate of TNF synthesis by granuloma-comprising cells,
including macrophages, DCs, B cells and T cells. Live granuloma
cells were first isolated (from the lungs of a group of 10 mice) by
using a Dead Cell Removal Kit (Miltenyi Biotec) and incubated at
37uC in a 5% CO2 humidified environment for 4–5 hours. TNF-a
proteinase inhibitor-1 (TAPI-1; Calbiochem) at a concentration of
100 mM was added to inhibit TNF release from cell membranes
[50,66]. PE-conjugated anti-TNF antibody (BioLegend) was then
used to stain 1610
6 cells at a sequence of time-points within a
3 hour period of TACE inhibition at 37uC.
The rate of mTNF synthesis for distinct TNF-producing cell
types was derived by nonlinear regression of the experimental data
to an equation of the form y=ae
bt + c as the general form of
Equation 10 (which is derived from Equation 3) using MATLAB.
Parameters a, b, c then were used to calculate k’TACE and ksynth.
½mTNF ~(½mTNF 0{
ksynth
k0
TACE
)e
{k0
TACEtz
ksynth
k0
TACE
ð10Þ
where [mTNF]0 is the steady-state initial number of mTNF on the cell
membrane and k’TACE is the TNF release rate constant in the presence
of TAPI-1 (k’TACE#kTACE). Knowing ksynth and the steady-state initial
number of mTNF [mTNF]0,t h ev a l u eo fkTACE can be calculated from:
½mTNF 0~
ksynth
kTACE
ð11Þ
Results
TNF availability within a granuloma
To understand the extent to which granuloma properties (e.g.
cellular composition, TNFR expression and the rate constant for
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tions were run for different values of model parameters within
ranges given in Table 3. Although TNF exists in different forms in
the granuloma, the amount of TNF associated with TNF
receptors, and in particular TNFR1, has been identified as a
primary factor that determines the outcomes of TNF signaling in
the granuloma [18,67]. Thus, we present steady state model
predictions for spatial profile of the fraction of sTNF-bound
TNFR1 in a granuloma using several different sample sets of
values for model parameters within ranges specified in Table 3
(Figure 3). Simulation results for the spatial profiles of other forms
of TNF in the model (soluble and cell-associated sTNF-bound
TNFR2 and internalized sTNF-bound TNFRs) are presented in
Supplementary Text S1 and Figure S2. Our modeling results
demonstrate that TNF availability in granuloma compartments is
dramatically influenced by the values of model parameters,
including rate constants for TNF/TNFR trafficking events, TNFR
densities and the rate of TNF synthesis in granuloma compart-
ments. However, modeling results here are limited in their
applicability due to parameter uncertainty, especially uncertainty
in the level of TNF and TNFR expression by distinct granuloma-
comprising cells. Therefore, we next turn to the identification of
critical model parameters that influence the outcome of the model,
TNF availability and binding to TNFRs in the granuloma.
Sensitivity analysis: identifying critical model parameters
that influence TNF availability
To identify parameters that significantly influence the availabil-
ity of TNF within a granuloma, sensitivity of the outputs of the
model describing TNF trafficking in a granuloma to changes of
input parameters was explored. Table 6 indicates significant
PRCC values for model parameters and outputs. For example, the
average sTNF-bound fraction of cell surface TNFR1 in the whole
granuloma (output 1) was shown to be significantly influenced by a
variety of parameters, including the average rate of mTNF
synthesis in the inner and outer compartments (ksynth_in and
ksynth_out), the average TNFR1 density in the inner and outer
compartments (R1_in, R1_out), the outer compartment fraction of
granuloma (f) as well as both TNF receptor affinities for sTNF (Kd1
and Kd2) and the rate constant for TNF-induced internalization of
TNFR1 (kint1). Indeed, using different values of these particular
parameters as inputs leads to outputs similar to those shown in
Figure 3 (data not shown). Thus, experimentally determined
values of these parameters are required for generation of useful
model predictions.
Parameters that positively correlate with the sTNF-bound
fraction of cell surface TNFR1 in the whole granuloma (output 1
in Table 6) include the rate of mTNF synthesis in both
compartments and the equilibrium dissociation constant of TNFR2
(Kd2) as a competitor of TNFR1 for binding to sTNF. Conversely,
TNFR1 internalization rate constant kint1, TNFR1 density in both
compartments, equilibrium dissociation constant of TNFR1 (Kd1),
and the outer compartment fraction of granuloma f negatively
correlate with this same output. Although greater affinity of TNFR1
for sTNF enhances the level of sTNF binding to TNFR1 in the core
ofgranuloma(output 2)asthe majorTNF-producingcompartment,
it reduces the access of TNFR1 on the membrane of cells in the
outer compartment to diffusing sTNF (output 3). Thus, increasing
the effective diffusion coefficient of sTNF in the granuloma
increases the sTNF-bound fraction of receptors in the outer
compartment. Diffusion of shed sTNF-bound TNFR2 complex
from the inner compartment to the outer compartment of
granuloma can also explain the positive correlation of TNFR2
density in the core with the sTNF-bound fraction of TNFR1 in the
outer compartment (output 3), while it is negatively correlated with
the same response in the inner compartment (output 2) due to
competition between receptors for binding to sTNF. Significant
correlations of model parameters with the level of free sTNF
concentration in the granuloma (output 4) are qualitatively similar
to their correlations with output 1, except for Kd1 and sTNF/
TNFR1 association rate constant kon1 that are, respectively,
positively and negatively correlated with output 4.
Applicability of the model will require that we have accurate
values of the significant parameters found via sensitivity analysis or
else we will have to consider the wide range of possibilities hinted
at in Figure 3. There are two different classes of these significant
parameters. One class includes parameters associated with TNF/
TNFR interactions and intracellular trafficking. The parameters of
this class have been theoretically estimated or experimentally
measured in multiple cell lines expressing TNF receptors. These
studies show that the time scales and thus the rates of significant
TNF/TNFR-associated processes identified above are consistent
over different cell lines. For example, the obtained TNF/TNFR
association and dissociation rate constants for TNFR1 and
TNFR2 on a variety of cell lines, including U937, HeLa, and
KYM-1 cells were found to be similar and consistent with the data
on mouse embryonic fibroblasts [42,52]. Further, internalization
of the sTNF/TNFR1 complex has been shown to occur with a
half-time of 10–20 minutes which gives an average value of
7.7610
24 s
21 for the TNFR1 internalization rate constant
[42,44]. The values of these parameters are given in Table 3 (in
parentheses). The second class of significant parameters are the
ones for which no experimental values are available and include
cellular fractions, the rate of mTNF synthesis and TNFR densities
on immune cells in a TB granuloma. Thus, we measure the values
of these parameters in an experimental model of TB granuloma.
Cellular composition of PPD bead granulomas
We used an artificial model of TB granuloma developed in mice
following injection of PPD-coated beads to measure model
Figure 3. Simulation results for the steady-state profile of
sTNF-bound fraction of cell surface TNFR1 in a granuloma
using seven different sample sets of parameter values within
ranges specified in Table 3. Arrow indicates radius of the bead
(rbead). Parameter values for the particular curves shown are listed in
Supplementary Table S2.
doi:10.1371/journal.pcbi.1000778.g003
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bead granulomas, multi-color flow cytometry with fluorescing
antibodies for specific immune cell surface markers was used as
described in Methods. Figure 4 indicates experimental data on
fractions of the major granuloma-comprising immune cells,
including DCs, macrophages, T cells and B cells, that compose
approximately 80% of the total cell population of day 2 and day 4
granulomas. Macrophages and B cells were observed to be the
largest cell populations in isolated granulomas. A small but
statistically significant increase (p,0.001) in the percentage of both
CD4 and CD8 T cells which represent the adaptive immune
response was observed in day 4 granulomas compared with day 2
granulomas. On the other hand, macrophages and DCs were
shown to form a slightly smaller portion of day 4 granuloma cell
population. The percentage of B cells in granulomas did not
significantly change from day 2 to day 4. Cellular composition of
the granuloma and the increase in the level of T cell recruitment
with time are qualitatively consistent with the experimental data
on the infiltration of immune cells into the lungs of mice infected
with Mtb as well as data on granulomas induced in lungs of Mtb-
infected monkeys, although T cell recruitment occurs in a shorter
time scale for PPD bead granulomas [7,9].
Quantification of TNFR densities
The average numbers of TNFR1 and TNFR2 molecules on the
membrane of day 2 and day 4 granuloma-comprising immune
cells were quantified by flow cytometry using standard PE-
conjugated beads as described in Methods. DCs, macrophages and
B cells were found to be the major TNFR-expressing cells in
granulomas with average TNFR1 density of the order of 10
3
molecules per cell and a lower level of expression for TNFR2
(Table 7). Further, except for lymphoid DCs and B cells that show
a significant decrease with time, the level of TNFR expression was
similar for day 2 and day 4 granuloma cells.
Quantification of the rate of mTNF synthesis
Using TAPI-1 as a TACE inhibitor to suppress the release of
TNF from the membrane of TNF-expressing cells over a 3 hour
time course, the rates of mTNF synthesis ksynth by different types of
immune cells in granulomas isolated at 2 and 4 days were
measured by flow cytometry as described in Methods. TAPI-1 at a
concentration of 100 mM was shown to partially suppress the
TACE-mediated release of TNF from the cell membrane, so that
the rate constant for TNF release after addition of TAPI-1 k’TACE
was not zero. A higher concentration of TAPI-1 (200 mM) has
Table 6. Significant PRCC values for model parameters and four spatially averaged steady-state outputs: (1) sTNF-bound fraction
of cell surface TNFR1 in the whole granuloma, (2) sTNF-bound fraction of cell surface TNFR1 in the inner compartment, (3) sTNF-
bound fraction of cell surface TNFR1 in the outer compartment, (4) sTNF concentration in the whole granuloma.
Parameter Parameter description Output (1) Output (2) Output (3) Output (4)
ksynth_in Average rate of mTNF synthesis in the inner compartment 0.93** 0.93** 0.71** 0.88**
ksynth_out Average rate of mTNF synthesis in the outer compartment 0.31** 0.82** 0.29**
R1_out TNFR1 density in the outer compartment 20.76** 20.85** 20.29**
R1_in TNFR1 density in the inner compartment 20.62** 20.86** 20.54** 20.76**
R2_out TNFR2 density in the outer compartment 20.17**
R2_in TNFR2 density in the inner compartment 20.09* 20.15** 0.25**
f Fraction of granuloma in the outer compartment 20.49** 20.32** 20.36**
D1 Diffusion coefficient of sTNF 0.19**
D2 Diffusion coefficient of shed TNF/TNFR2 complex 0.08*
w Volume fraction of the extracellular space per granuloma volume
dG Density of granulomas in the lung tissue
kTACE Rate constant for TNF release by TACE activity
Kd1 Equilibrium dissociation constant of sTNF/TNFR1 20.12** 20.18** 0.16** 0.72**
Kd2 Equilibrium dissociation constant of sTNF/TNFR2 0.14** 0.18** 0.09*
kon1 sTNF/TNFR1 association rate constant 20.47**
kon2 sTNF/TNFR2 association rate constant
kint1 TNFR1 internalization rate constant 20.76** 20.72** 20.75** 20.42**
kint2 TNFR2 internalization rate constant
kshed TNFR2 shedding rate constant
krec1 TNFR1 recycling rate constant 20.09*
krec2 TNFR2 recycling rate constant 0.09*
kt1 TNFR1 turn-over rate constant
kt2 TNFR2 turn-over rate constant
kdeg1 TNFR1 degradation rate constant
kdeg2 TNFR2 degradation rate constant
Non-significant PRCC values are not indicated.
*0.001,p-value,0.05.
**p-value,0.001.
doi:10.1371/journal.pcbi.1000778.t006
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TNF from the membrane of human peripheral blood T cells
[50,66]. However, we found that high concentrations of TAPI-1
induce cell death. Thus, the rate of mTNF synthesis by each cell
type was quantified by fitting experimental data to Equation 10 as
described in Methods and shown in Figure 5. The results of the fit
for ksynth, kTACE and k’TACE from three experiments are averaged
and reported in Table 8. Interestingly, PPD-bead granuloma T
cells and B cells did not express quantifiable amounts of mTNF,
although proinflammatory T cells have been reported to produce
TNF in Mtb-infected mice [68]. To our knowledge, this is the first
experimental quantification of the rate of TNF synthesis by
granuloma-comprising immune cells.
TNF/TNFR binding and trafficking dynamics and cellular
organization control TNF availability within a granuloma
In general, the differences between experimental data on day 2
and 4 granulomas, although significant, are fairly small. Thus,
using our data on cellular composition, cell-specific rates of mTNF
synthesis and TNFR densities from day 4 PPD-bead granulomas
as well as literature data on TNF/TNFR kinetic parameter
estimates as inputs to our model, we studied mechanisms that
control steady state TNF availability within a TB granuloma. Here
we illustrate the role of two important factors, (i) molecular level
processes governing TNF/TNFR interactions and intracellular
dynamics and (ii) cellular organization within the granuloma, in
regulating TNF availability within a granuloma.
To study the influence of TNF-associated molecular level
processes on the availability of TNF, and thus TNF signaling
within a TB granuloma, the distribution of sTNF in a granuloma
was calculated by comparing modeling results in the presence of
TNF intracellular trafficking with results of the model in the
absence of TNF/TNFR internalization and shedding or TNF
binding to TNF receptors. Figure 6A compares the spatial
distributions of free sTNF at steady state for each case. TNF/
TNFR reactions and interactions significantly affect the available
amount of sTNF in a granuloma. Reversible binding of sTNF to
cell surface receptors can reduce the amount of available
extracellular sTNF in the granuloma by approximately two-fold.
However, other molecular processes including the intracellular
Table 7. Average numbers of TNF receptors per cell quantified by multi-color flow cytometry for different types of granuloma-
comprising immune cells isolated from 15 mice.
Cell type Number of receptors at day 2 Number of receptors at day 4
TNFR1 TNFR2 TNFR1 TNFR2
Lymphoid dendritic cells 460061100 19006600 17006500 170061100
Myeloid dendritic cells 15006400 5006200 17006400 7006300
Macrophage 10006300 4006200
* 10006300 5006200
B cells 11006600 9006200 5006200 2006100
*
CD4 T cells 3006100
* 4006100
* 2006100
* 2006100
*
CD8 T cells 3006100
* 2006100
* 1006100
* 2006100
*
*PE fluorescence intensity was smaller than the fluorescence intensity of the QuantiBRITE standard beads with the smallest number of conjugated PE molecules.
doi:10.1371/journal.pcbi.1000778.t007
Figure 4. Cellular fractions in PPD bead granulomas at 2 and 4 days of granuloma formation in thirty CBA/J mice quantified by
multi-color flow cytometry. Results are expressed as the percentage of each cell type in the total population of granuloma cells. Error bars
represent standard deviation from the mean.
doi:10.1371/journal.pcbi.1000778.g004
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of magnitude in the extracellular concentration of sTNF compared
with the case in which TNF is produced and diffuses in a
granuloma without binding to cell surface receptors. This result is
consistent with experimental data on the role of TNFRs in
modulating the biologic activity of TNF where a reduction of more
than one order of magnitude in serum TNF levels of LPS-
challenged control mice compared with TNFR-deficient mice has
been observed [17].
Numerous studies have shown that TB granulomas, especially
in humans as well as guinea pig and non-human primate models
[9,10], form as organized structures composed of a core of
macrophages and DCs surrounded by a ring of lymphocytes.
However, the effect of such a specific cellular organization on
trafficking and availability of cytokines, in particular TNF, in the
granuloma microenvironment has not been studied. To demon-
strate the effect of spatial organization of immune cells on TNF
availability in a granuloma, we performed simulations for varying
levels of separation index (s) between populations of macrophages/
DCs and lymphocytes within the granuloma (see Methods for
more information). Our modeling results show that in the presence
of TNF/TNFR binding and intracellular trafficking, the organi-
zation of cells within a granuloma significantly influences the
availability of TNF. As such, greater levels of separation between
Figure 5. Quantification of the rate of mTNF synthesis by each cell type. Experimental data on the number of mTNF molecules on the
surface of each cell type after addition of TAPI-1 were fitted to Equation 10 to estimate ksynth for that cell type. Displayed data represent TNF synthesis
by day 4 granuloma cells for three hours in the presence of TAPI-1. Error bars indicate standard deviations. Values of R
2 for curve fitting for mDCs,
macrophages and pDCs are 0.97, 0.99 and 0.98, respectively.
doi:10.1371/journal.pcbi.1000778.g005
Table 8. Average rate of mTNF synthesis and average rate constant for TNF release quantified by multi-color flow cytometry for
different types of TNF-expressing immune cells (isolated from 10 mice) isolated from day 2 and 4 granulomas.
Cell type ksynth (#/cell.sec): day 2 ksynth (#/cell.sec): day 4 kTACE (s
21)
* k’TACE (s
21)
*
Lymphoid dendritic cells 1.0160.74 0.8160.35 (4.2361.23)610
24 (3.2760.87)610
24
Myeloid dendritic cells 0.2660.21 0.2160.05 (4.4961.86)610
24 (3.0961.45)610
24
Macrophage 0.1760.09 0.1560.03 (4.5561.36)610
24 (3.1861.16)610
24
*Values of kTACE and k’TACE were averaged over all data on day 2 and day 4 granuloma cells.
doi:10.1371/journal.pcbi.1000778.t008
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at 1) result in steeper gradients of TNF concentration in the
granuloma (Figure 6A). When the granuloma is organized in this
way, the granuloma core (which is completely or almost
completely composed of macrophages and DCs) is exposed to a
higher concentration of TNF, while the mantle (which is
composed of lymphocytes) is exposed to a lower concentration of
TNF in comparison with the case of a zero separation index
(reflecting a well-mixed cellular organization). A similar effect is
observed for the number of sTNF-bound cell surface TNFR1 that
controls the type and level of TNF-induced cell response in the
granuloma (Figure 6B). For sufficiently large separation indices, a
greater fraction of TNFR1 molecules on the membrane of
macrophages and DCs in the granuloma core bind to sTNF in
comparison with lymphocytes in the outer compartment. These
results demonstrate that molecular level processes, including TNF
intracellular trafficking and TNF receptor recycling, together with
how immune cells (with different levels of TNF and TNF receptor
expression) are organized within the granuloma control the
amount of available TNF for each cell type and thus cell-specific
TNF signaling.
Effect of TNF-neutralizing drugs on availability of TNF
within a granuloma
In order to study the effects of TNF-neutralizing drugs with
various properties on the availability of TNF in a granuloma, we
model a hypothetical TNF-neutralizing drug as an agent that
diffuses from surrounding tissue into the granuloma, binds to TNF
molecules and inhibits sTNF from binding to TNF receptors. We
investigated how the efficiency of TNF neutralization (defined by
Equation 9) by anti-TNF drugs is influenced by drug properties,
including drug/TNF association and dissociation kinetics, drug
ability to bind to mTNF, and drug/TNF binding stoichiometry.
Three classes of hypothetical drugs with defined properties were
modeled loosely based on properties of human TNF-neutralizing
drugs (e.g. infliximab and etanercept) and their efficiencies of TNF
neutralization were compared. Since the general behavior of all
classes of drugs was shown to be independent of cellular
organization in the granuloma (data not shown), model results
for a separation index of one are discussed below.
Class 1: drug binding to only sTNF at a binding ratio of
1:1
We first consider a drug that binds to sTNF with a binding ratio
of 1:1, inhibiting it from binding to both TNFR1 and TNFR2.
The effects of varying association and dissociation rate constants
(kon_sTNF/drug and koff_sTNF/drug) for sTNF and drug are shown in
Figure 7A. Model results show that depending on sTNF/drug
association and dissociation rate constants, 0%–50% of total
available sTNF in a granuloma can be neutralized. As expected,
drugs with greater affinities for sTNF more efficiently neutralize
TNF in the granuloma. Interestingly, increasing kon_sTNF/drug
without changing drug affinity leads to an increase in the drug
neutralization efficiency (Figure 7D, Class 1). This is because drugs
compete with cell surface TNFRs for binding to sTNF and thus a
drug with a greater kon_sTNF/drug can neutralize larger amounts of
sTNF.
Class 2: drug binding to both sTNF and mTNF at a
binding ratio of 1:1
We next consider a drug that binds to both sTNF and mTNF
with a binding ratio of 1:1. We assumed identical association and
dissociation rate constants for drug binding to mTNF and sTNF.
TACE activity was considered independent of whether mTNF is
bound to drug or not. Model results show that at all values of
TNF/drug association and dissociation rate constants, a drug with
the ability to bind to both sTNF and mTNF is more efficient in
neutralizing TNF in a granuloma compared with a drug that can
only bind to sTNF (compare Figures 7A and 7B). In other words,
our model results demonstrate that even if sTNF is considered as
the primary form of TNF that controls TNF-mediated signaling in
granuloma cells, binding to mTNF is an important determinant of
TNF neutralization power of the drug. This can be explained by
Figure 6. Predictions of the two-compartment model for a PPD bead granuloma. (A) The effects of receptor binding, intracellular
trafficking of TNF and cellular organization within granuloma (represented by separation) on the steady state spatial distribution of free sTNF in a
granuloma. (B) The effect of separation between different cell types in a granuloma on the spatial concentration of sTNF-bound cell surface TNFR1.
Parameter values for the rate of mTNF synthesis (and similarly for TNFR densities) in each compartment were computed via Equations 6 and 7, using
experimental data for day 4 granulomas presented in Figure 4 and Tables 7 and 8. Other parameter values are as listed in Table 3. The qualitative
aspects of these plots are similar for day 2 granulomas.
doi:10.1371/journal.pcbi.1000778.g006
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of competition effects of cell surface TNFRs. However, similar to
the case of Class 1 drug tested, TNF neutralization most efficiently
occurs for a drug with the highest affinity for TNF.
Interestingly, among drugs with a constant affinity of Kd=10
29 M
there is an optimum in neutralization efficiency that occurs for a drug
with approximate values of kon_TNF/drug=5.6 610
4 M
21s
21 and
koff_TNF/drug=5.6 610
25 s
21 (Figure 7D, Class 2). To explain this
result, we need to note that an mTNF/drug complex can be released
into extracellular spaces due to TACE activity and then acts as a
source for sTNF in the granuloma. When TNF/drug association is
sufficientlyrapid,drugbindingtomTNFoccursbeforemTNFcanbe
released into extracellular spaces. Thus, a significant proportion of
sTNF in the granuloma is produced only after dissociation of sTNF
from mTNF/drug complexes that are released from the cell
membrane. In other words, the drug exerts a delay in the release of
available sTNF from the cell membrane. Under these conditions,
increasing TNF/drug dissociation rate constant increases the amount
of sTNF dissociated from extracellular TNF/drug complexes and
reduces the efficiency of TNF neutralization. This can explain why a
drug of Class 2 type with intermediate values of TNF association and
dissociation rate constants can more efficiently neutralize TNF
compared with drugs of the same Class with the same affinity for
TNF but higher values of these rate constants.
Class 3: drug binding to both sTNF and mTNF at a
binding ratio of 3:1
Finally, we considered a drug that binds to both trimeric sTNF
and mTNF molecules that possess three binding sites for the drug.
An sTNF molecule with either one, two or three drug molecules
bound is neutralized and not able to bind TNFR1 or TNFR2.
This assumption helps us compare modeling results for TNF
neutralization by different classes of drugs. Further, this assump-
tion is consistent with experimental data indicating that only
Figure 7. Model predictions for the effect of TNF-neutralizing drugs with various properties on the availability of TNF within a
granuloma. (A) Class 1: the drug can only bind to sTNF with a binding ratio of 1:1. (B) Class 2: the drug can bind to both mTNF and sTNF with a
binding ratio of 1:1. The star shows the location of a drug with TNF binding kinetics similar to etanercept. (C) Class 3: the drug can bind to both mTNF
and sTNF with a binding ratio of 3:1. The star shows the location of a drug with TNF binding kinetics similar to infliximab. (D) Model predictions for
the effect of TNF/drug association rate constant on neutralization efficiency of drugs of different classes but identical affinities (Kd_Drug=koff_TNF/Drug/
kon_TNF/Drug=10
29 M). Model parameter values are the same as Figure 6. TNF neutralization-associated parameter values are as listed in Table 4.
doi:10.1371/journal.pcbi.1000778.g007
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and artificially prepared dimeric TNF do not efficiently trigger
TNF signaling in cells [69,70]. We investigated the effect of
multiple binding sites for drug binding to TNF and formation of
larger drug/TNF complexes on the efficiency of TNF neutraliza-
tion in a granuloma. Model results show that the drug
concentration in the lung tissue is large enough that this greater
drug/TNF binding ratio does not limit availability of the drug for
binding to free TNF molecules. Thus, at large values of TNF/drug
association rate constant, a higher binding ratio (i.e. 3:1) increases
the efficiency of TNF neutralization in comparison to a drug of
Class 2 type with a binding ratio of 1:1 (compare Figures 7B and
7C). However, binding stoichiometry does not significantly
influence the level of TNF neutralization at low values of TNF/
drug association rate constant, where TNFRs dominate the drug
in competition for binding to sTNF (Figure 7C). An optimum in
neutralization efficiency amongst Class 3 drugs of the same affinity
Kd=10
29 M occurs in the same range of TNF/drug association
and dissociation rate constants as observed for Class 2 (Figure 7D).
Discussion
We have developed a two-compartment mathematical model
that captures the structural features of a TB granuloma based on
an experimental mouse PPD bead model and also includes
molecular processes that govern the intracellular and extracellular
trafficking of TNF. The model includes fine grain details at the
level of TNF receptor dynamics, while using a coarse grain
description for cellular level details representing a snapshot in time
of a granuloma comprised of a static number of immune cells. This
is based on a significant difference between the time-scale of TNF/
TNFR associated molecular processes studied here and cellular
level events that may change the structure of a granuloma (e.g. cell
recruitment, migration and death).
The detailed consideration of synthesis, diffusion, receptor
binding and intracellular trafficking of TNF within the heteroge-
neous three-dimensional structure of a granuloma distinguishes
our model from a previous study by Marino et al on the role of
TNF in host defense against TB [28]. The model developed by
Marino et al describes the temporal dynamics of the immune
response to Mtb infection in active and latent phases within a time
course of 500 days by inclusion of TNF immunological functions
on macrophages and T cells. However, we focus in this study on a
snapshot in time of a granuloma to study the steady state spatial
distribution of available TNF. We used results of our model
sensitivity analysis as a novel tool to lead experiments to measure
critical model parameters in artificial granulomas induced in the
lungs of mice following injection of mycobacterial PPD-coated
beads. Finally, whereas TNF neutralization has been simulated by
Marino et al via removing fractions of available sTNF and/or
mTNF, we studied the effects of TNF-neutralizing drugs by
incorporation of their mTNF and/or sTNF binding kinetics and
stoichiometry.
Model analysis helped us characterize two mechanisms for
controlling the availability of TNF within a granuloma. These
mechanisms include intracellular trafficking of TNF via internaliza-
tion of recyclable TNFRs, and specific cellular organization within
the granuloma, i.e. the level of separation between different classes of
cells. Further, we demonstrated that for the resulting effect of cellular
organization on spatial distribution of available TNF in the
granuloma to be significant, intracellular trafficking of TNF is
essential (Figure 6A). Hence, the spatial heterogeneity in the level of
TNF and TNFR expression, and thus the amount of TNF
internalization that occurs as a result of specific organization of
differentcelltypesinthegranulomacontrolsthespatialdistributionof
the available amount of TNF for signaling for each specific cell type.
For sufficiently large values of the separation index in the
granuloma, the model predicts significantly greater levels of sTNF
binding to TNFR1 on the membrane of macrophages/DCs in the
core compared with lymphocytes in the mantle (Figure 6B), which
might be important for spatially coordinating the TNF-induced
immunological functions for cells in a granuloma. Rangamani and
Sirovich have recently shown via mathematical modeling that the
induction of the two major TNF-induced signaling pathways, the
caspase-mediated apoptotic pathway and the NF-kB-mediated
survival pathway, are primarily controlled at the level of TNF/
TNFR1 interactions [71]. As such, very low initial concentrations
of TNF (i.e. less than 10
211 M) that can activate only a limited
number of cell surface TNFR1 molecules are not capable of
inducing apoptosis in the cells [52]. However, efficient NF-kB
activation has been reported at TNF concentrations as low as
10
213 M based on both modeling [72] and experimental analysis
of TNF signaling in HL60 cells and 3T3 mouse embryonic
fibroblasts [73,74]. Further, TNF/TNFR2 interactions have been
shown to enhance TNFR1-dependent activation of caspase-
mediated apoptotic pathway [75,76]. These suggest a differential
induction of apoptotic and survival signaling pathways between
the granuloma core that is comprised of macrophages/DCs and
the surrounding ring of lymphocytes.
The hypothesis of differential induction of TNF-mediated
signaling pathways for classical granulomas such as ones observed
particularly in human, nonhuman primate and guinea pig models
of TB [9,10] has immunological implications. Whereas TNF-
induced apoptosis of granuloma core macrophages that contain
pathogenic mycobacteria is required for antigen cross-presentation
and subsequent T cell priming and helps eliminate the pathogen
[77,78], lymphocyte (especially CD4 and CD8 T cell) death by
TNF-induced apoptosis has been reported as one of the important
components of an ineffective immune response against mycobac-
terial infections [79,80]. However, the TNF-induced survival
signaling pathway is required for retaining T cells at the
developing granuloma site where they produce IFN-c, activating
macrophages in synergy with TNF to kill intracellular infections
[81]. Thus, our novel hypothesis is that a separate cellular
organization in the granuloma may favor an efficient immune
response via spatially coordinating the TNF-induced immunolog-
ical functions in the granuloma (Figure 8). Consistent with our
hypothesis, very few apoptotic lymphocytes in classical TB
granulomas induced in the guinea pig have been detected and
most apoptotic cells have been seen close to the core of
granulomas [82]. Further, because cellular organization undergoes
dynamic changes with granuloma development and at different
stages of immune response (innate versus adaptive) to TB
infection, it can be a factor controlling the diverse activities of
TNF according to the stage of infection in the lung tissue.
Finally, we used the model to predict and analyze the effects of
TNF-neutralizing drugs with different properties on the availabil-
ity of TNF within a developed granuloma. Average serum
concentration of two murine analogs of human TNF blockers,
infliximab and etanercept, after a single dose of drug, has been
reported to be on the order of 10
27–10
26 M [64]. Using this
reported concentration to estimate the tissue level concentration of
these drugs (Table 4), we demonstrated that the efficiency of TNF
neutralization within the granuloma not only depends on the
affinity of the drug for TNF, but also on the ability of the drug to
bind to mTNF versus sTNF, the rate constants for drug/TNF
association and dissociation reactions as well as the drug/TNF
binding stoichiometry (Figure 7).
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regarding experimentally observed differences in the neutralizing
power of the two major human TNF blockers, infliximab and
etanercept, based on their TNF binding specificities. Infliximab is a
chimeric monoclonal TNF antibody that binds potently to both
sTNFand mTNF. Up to three infliximab molecules can bind to one
trimeric TNF molecule. Etanercept is a TNF receptor p75-IgG
fusion protein that can also bind to both trimeric sTNF and mTNF.
However, two receptor arms of etanercept contact two of the three
receptor binding sites on different faces of the trimeric TNF, leading
to a binding molar ratio of 1:1 for TNF/etanercept binding.
Further, etanercept has greater TNF association and dissociation
rate constants in comparison with infliximab [48,83,84]. Hence,
based on the classification of TNF-neutralizing drugs we presented
in this paper, infliximab and etanercept can be considered as drugs
of Class 3 and Class 2 types, respectively. Given the TNF binding
stoichiometries and reported TNF association/dissociation rate
constants for infliximab and etanercept (infliximab: kon_TNF/drug=
5.7610
4 M
21s
21, koff_TNF/drug=1.1610
24 s
21 and etanercept:
kon_TNF/drug=2.6610
5 M
21s
21, koff_TNF/drug=1.3610
23 s
21) [84],
our granuloma model predicts TNF neutralization efficiencies of
0.90 and 0.39 for drugs with identical TNF binding properties to
infliximab and etanercept, respectively; these efficiencies are
marked with stars on Figures 7B, C. This is consistent with the
reported higher TNF neutralization power of the TNF antibody
(analog of infliximab) in comparison with the TNF receptor fusion
molecule (analog of etenercept) in chronically Mtb-infected mice
[85]. Although decreased penetration of the receptor fusion
molecule into the lungs compared with antibody has been
hypothesized to be a reason for the higher TNF neutralization
power of antibody [85], we did not observe a significant change in
the neutralization efficiency of simulated drug analogs by changing
drug permeability in the granuloma (kc) by up to two order of
magnitude (data not shown). Thus, the difference in binding
properties of infliximab and etanercept must be considered when
explaining the higher rate of TB reactivation induced from
infliximab treatments in comparison with etanercept, although we
anticipate that differential functional properties such as induction of
apoptosis in TNF-producing cells by infliximab but not etanercept
further influence the outcome of anti-TNF treatments [46,86].
Although we have focused this study primarily on molecular
and cellular scale processes within a snapshot of time in a
granuloma, it will be necessary to consider multiple time and
length scales (including dynamics in the lymphatic system) to
further examine the role of TNF and anti-TNF therapies in the
process of granuloma development and maintenance. We are
currently working on this multi-scale approach [87].
Supporting Information
Text S1 Simulation results for the spatial profiles of different
forms of TNF in the model
Found at: doi:10.1371/journal.pcbi.1000778.s001 (0.03 MB
DOC)
Table S1 Parameters defined or modified based on incorpora-
tion of different cell types in the granuloma model
Found at: doi:10.1371/journal.pcbi.1000778.s002 (0.07 MB
DOC)
Table S2 Parameter sets used to generate curves on Figure 3
Found at: doi:10.1371/journal.pcbi.1000778.s003 (0.04 MB
DOC)
Figure 8. Spatial coordination of the TNF-induced immunological functions in a classical granuloma composed of a core of
macrophages and DCs surrounded by a ring of lymphocytes. Great availability of TNF in the core of granuloma (together with TNF-induced
TNFR2 activation) can turn on the TNFR1-dependent caspase-mediated apoptotic pathway that favors antigen cross-presentation as well as
elimination of the pathogen inside the granuloma. Low level of TNF availability in the mantle of granuloma is sufficient to turn on the NF-kB signaling
which favors cell survival and expression of pro-inflammatory genes but not the apoptotic pathway.
doi:10.1371/journal.pcbi.1000778.g008
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in the two-compartment model of PPD-bead granuloma. (A)
Parameter s (separation index) is defined as indicated in Equation
(5) to present the level of separation between different cell types in
the granuloma model (other than sensitivity analysis) when all cell
types are present. A separation index (s) of 0 is equivalent to a
totally mixed cellular organization. Increasing s leads to an
increase in the level of separation in the cellular organization as
s=1 represents a cellular organization in which macrophages and
DCs are separate from but surrounded by lymphocytes. (B)
Parameter f is defined as the fraction of cellular granuloma in the
outer compartment and is only used when distinct cell types are
not considered in the model (e.g. in sensitivity analysis). Increasing
f results in a decrease in rcore while rbead and rg are maintained
constant.
Found at: doi:10.1371/journal.pcbi.1000778.s004 (2.14 MB TIF)
Figure S2 Simulation results for the steady-state concentration
profiles of the model species, including sTNF, sTNF/TNFR2shed,
sTNF-bound and internalized TNFRs in a granuloma for two sets
of parameter values: (A), (B) ksynth_in=1#/cell.s, ksynth_out=0.01 #/
cell.s, R1_in=R2_in=R1_out=R2_out=2000 #/cell. (C), (D)
ksynth_in=ksynth_out=0.1 #/cell.s, R1_in=R2_in=R1_out=500 #/cell
, R2_out=5000 #/cell. For both simulations, s=1 and f=0.5.
Other parameter values are as listed in Table 3. Arrows indicate
radius of the bead (rbead) and radius at which the two compartments
are separated (rcore).
Found at: doi:10.1371/journal.pcbi.1000778.s005 (2.22 MB TIF)
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